| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/05/2022 | -11.51% | Barclays | $3 → $5 | Upgrades | Underweight → Equal-Weight |
| 08/02/2022 | 41.59% | Raymond James | → $8 | Upgrades | Market Perform → Outperform |
| 05/24/2022 | -64.6% | Goldman Sachs | $3 → $2 | Maintains | Sell |
| 05/17/2022 | -46.9% | Morgan Stanley | $5 → $3 | Maintains | Underweight |
| 05/10/2022 | -46.9% | Barclays | $4 → $3 | Maintains | Underweight |
| 04/06/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 04/06/2022 | 41.59% | SVB Leerink | $10 → $8 | Maintains | Market Perform |
| 03/08/2022 | 41.59% | Wells Fargo | $12 → $8 | Maintains | Equal-Weight |
| 03/07/2022 | -11.51% | Morgan Stanley | $6 → $5 | Maintains | Underweight |
| 03/07/2022 | -29.21% | Barclays | $13 → $4 | Downgrades | Equal-Weight → Underweight |
| 03/07/2022 | 76.98% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 76.98% | Morgan Stanley | $11 → $10 | Maintains | Underweight |
| 11/08/2021 | 76.98% | Goldman Sachs | $23 → $10 | Downgrades | Neutral → Sell |
| 11/08/2021 | 130.08% | Barclays | $20 → $13 | Maintains | Equal-Weight |
| 11/08/2021 | 94.68% | Morgan Stanley | → $11 | Downgrades | Equal-Weight → Underweight |
| 09/22/2021 | 307.07% | Mizuho | $29 → $23 | Maintains | Buy |
| 08/10/2021 | 253.97% | Canaccord Genuity | $86 → $20 | Downgrades | Buy → Hold |
| 08/10/2021 | 307.07% | Goldman Sachs | $63 → $23 | Downgrades | Buy → Neutral |
| 08/10/2021 | 342.46% | Wells Fargo | $60 → $25 | Downgrades | Overweight → Equal-Weight |
| 07/16/2021 | 519.45% | Morgan Stanley | $36 → $35 | Maintains | Equal-Weight |
| 07/01/2021 | 519.45% | Berenberg | → $35 | Downgrades | Buy → Hold |
| 04/19/2021 | 537.15% | Morgan Stanley | $45 → $36 | Maintains | Equal-Weight |
| 03/29/2021 | 1174.29% | SVB Leerink | $69 → $72 | Maintains | Outperform |
| 03/10/2021 | 1121.2% | Mizuho | $34 → $69 | Upgrades | Neutral → Buy |
| 03/02/2021 | 696.43% | Morgan Stanley | $50 → $45 | Maintains | Equal-Weight |
| 02/17/2021 | 590.24% | JP Morgan | $76 → $39 | Downgrades | Overweight → Neutral |
| 11/11/2020 | 1032.7% | Berenberg | → $64 | Initiates Coverage On | → Buy |
| 11/11/2020 | 784.92% | Morgan Stanley | $68 → $50 | Maintains | Equal-Weight |
| 11/05/2020 | 873.42% | Piper Sandler | $70 → $55 | Maintains | Neutral |
| 11/05/2020 | 1333.58% | B of A Securities | $100 → $81 | Maintains | Buy |
| 11/05/2020 | 1652.15% | SVB Leerink | $133 → $99 | Maintains | Outperform |
| 11/05/2020 | 891.12% | BMO Capital | → $56 | Downgrades | Outperform → Market Perform |
| 10/20/2020 | 2076.91% | Mizuho | → $123 | Initiates Coverage On | → Buy |
| 08/10/2020 | 1103.5% | Morgan Stanley | $73 → $68 | Maintains | Equal-Weight |
| 08/06/2020 | 1811.44% | BMO Capital | $112 → $108 | Maintains | Outperform |
| 08/06/2020 | 1333.58% | Wedbush | $89 → $81 | Maintains | Outperform |
| 07/13/2020 | 1669.85% | B of A Securities | $104 → $100 | Maintains | Buy |
| 06/12/2020 | 2253.9% | SVB Leerink | $129 → $133 | Maintains | Outperform |
| 05/28/2020 | 1191.99% | Morgan Stanley | $69 → $73 | Maintains | Equal-Weight |
| 05/28/2020 | 2183.11% | SVB Leerink | $125 → $129 | Maintains | Outperform |
| 05/13/2020 | 1669.85% | RBC Capital | → $100 | Initiates Coverage On | → Outperform |
| 05/12/2020 | 1882.23% | BMO Capital | $107 → $112 | Maintains | Outperform |
| 04/15/2020 | 1121.2% | Morgan Stanley | $92 → $69 | Maintains | Equal-Weight |
| 03/27/2020 | 1138.89% | Stifel | $94 → $70 | Upgrades | Hold → Buy |
| 02/26/2020 | 1528.26% | Morgan Stanley | $100 → $92 | Maintains | Equal-Weight |
| 02/19/2020 | 1563.66% | Stifel | $96 → $94 | Maintains | Hold |
| 02/03/2020 | 1669.85% | Evercore ISI Group | $86 → $100 | Upgrades | In-Line → Outperform |
| 12/13/2019 | 2289.3% | Oppenheimer | → $135 | Upgrades | Perform → Outperform |
| 12/09/2019 | 2731.76% | Wells Fargo | $242 → $160 | Maintains | Overweight |
| 11/26/2019 | 2006.12% | SVB Leerink | → $119 | Upgrades | Market Perform → Outperform |
| 11/19/2019 | 1422.07% | Evercore ISI Group | → $86 | Downgrades | Outperform → In-Line |
| 11/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 11/01/2019 | 1404.37% | Piper Sandler | $120 → $85 | Maintains | Neutral |
| 11/01/2019 | 1669.85% | Morgan Stanley | $104 → $100 | Maintains | Equal-Weight |
| 10/11/2019 | 1740.64% | Morgan Stanley | $136 → $104 | Maintains | Equal-Weight |
| 10/01/2019 | 1829.14% | Stifel | → $109 | Initiates Coverage On | → Hold |
| 08/12/2019 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/06/2019 | 2306.99% | Morgan Stanley | $143 → $136 | Maintains | Equal-Weight |
| 06/18/2019 | 2731.76% | Maxim Group | → $160 | Upgrades | Hold → Buy |
| 06/17/2019 | 2784.85% | BMO Capital | $191 → $163 | Maintains | Outperform |
| 05/15/2019 | 2218.5% | Wedbush | $166 → $131 | Downgrades | Outperform → Neutral |
| 03/05/2019 | — | Leerink Swann | Downgrades | Outperform → Market Perform | |
| 02/26/2019 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 01/23/2019 | 2749.46% | Canaccord Genuity | $250 → $161 | Maintains | Buy |
| 12/20/2018 | — | Raymond James | Initiates Coverage On | → Strong Buy | |
| 12/19/2018 | 2112.31% | Morgan Stanley | $185 → $125 | Maintains | Equal-Weight |
| 12/06/2018 | 2023.82% | Piper Sandler | $240 → $120 | Downgrades | Overweight → Neutral |
| 11/28/2018 | 2466.28% | Leerink Swann | → $145 | Initiates Coverage On | → Outperform |
| 11/05/2018 | 3174.22% | Morgan Stanley | $186 → $185 | Maintains | Equal-Weight |
| 11/05/2018 | 2837.95% | Wedbush | $204 → $166 | Maintains | Outperform |
| 11/05/2018 | 2908.74% | Janney Montgomery Scott | $170 → $170 | Upgrades | Neutral → Buy |
| 10/15/2018 | 3191.92% | Morgan Stanley | $190 → $186 | Maintains | Equal-Weight |
| 06/19/2018 | 3970.65% | Evercore ISI Group | $175 → $230 | Upgrades | In-Line → Outperform |
| 05/31/2018 | 4147.64% | Piper Sandler | → $240 | Assumes | Overweight → Overweight |
| 05/03/2018 | 3722.87% | BMO Capital | $222 → $216 | Maintains | Outperform |
| 03/21/2018 | 3598.98% | Morgan Stanley | $152 → $209 | Maintains | Equal-Weight |
| 03/14/2018 | 3793.67% | Janney Montgomery Scott | → $220 | Initiates Coverage On | → Neutral |
| 03/05/2018 | 4183.03% | William Blair | → $242 | Initiates Coverage On | → Outperform |
| 02/26/2018 | 2590.17% | Morgan Stanley | $151 → $152 | Maintains | Equal-Weight |
| 02/22/2018 | 3758.27% | B of A Securities | $185 → $218 | Maintains | Neutral |
| 02/22/2018 | 3829.06% | BMO Capital | $215 → $222 | Maintains | Outperform |
| 01/25/2018 | — | Leerink Swann | Downgrades | Outperform → Market Perform | |
| 12/21/2017 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 12/13/2017 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/11/2017 | — | Jefferies | Upgrades | Hold → Buy | |
| 12/05/2017 | 3475.09% | Canaccord Genuity | → $202 | Initiates Coverage On | → Buy |
| 11/30/2017 | 3439.7% | Maxim Group | $170 → $200 | Maintains | Buy |
| 11/06/2017 | — | Evercore ISI Group | Downgrades | Outperform → In-Line | |
| 11/03/2017 | 2784.85% | SunTrust Robinson Humphrey | $108 → $163 | Maintains | Buy |
| 11/03/2017 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
| 11/02/2017 | 2767.16% | Barclays | $151 → $162 | Maintains | Overweight |
| 11/02/2017 | — | BTIG | Upgrades | Neutral → Buy | |
| 10/30/2017 | 2767.16% | BMO Capital | $134 → $162 | Maintains | Outperform |
| 10/16/2017 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 10/11/2017 | — | Jefferies | Downgrades | Buy → Hold | |
| 10/02/2017 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
| 09/07/2017 | 2572.47% | Barclays | → $151 | Initiates Coverage On | → Overweight |
| 08/17/2017 | 1705.25% | Evercore ISI Group | → $102 | Initiates Coverage On | → In-Line |
| 08/07/2017 | 1758.34% | Morgan Stanley | $103 → $105 | Maintains | Equal-Weight |
bluebird bio Questions & Answers
What is the target price for bluebird bio (BLUE)?
The latest price target for bluebird bio (NASDAQ: BLUE) was reported by Barclays on August 5, 2022. The analyst firm set a price target for $5.00 expecting BLUE to fall to within 12 months (a possible -11.51% downside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for bluebird bio (BLUE)?
The latest analyst rating for bluebird bio (NASDAQ: BLUE) was provided by Barclays, and bluebird bio upgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for bluebird bio (BLUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on August 5, 2022 so you should expect the next rating to be made available sometime around August 5, 2023.
Is the Analyst Rating bluebird bio (BLUE) correct?
While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a upgraded with a price target of $3.00 to $5.00. The current price bluebird bio (BLUE) is trading at is $5.65, which is out of the analyst's predicted range.
